fbpx

molecules of the month

PF-06843195

oral PI3K_-selective kinase inhibitor prodrug

preclinical candidate for breast cancer

from mining of prior PI3K inh., SBDD, and opt.

J. Med. Chem., Dec. 24, 2020

Pfizer, San Diego, CA

Structure of oral PI3K_-selective kinase inhibitor prodrug PF-06843195
1 min read

Pfizer oral PI3ka-selective kinase inhibitor prodrug


request a trial

You don’t have time to read everything, but you can’t afford to fall behind.

Drug Hunter Premium is drug discovery, distilled, so you can quickly catch up and make informed decisions based on industry examples.

Get ahead now by requesting a trial.


already a member? log in: